GIMV Valuation Multiples

Discover GIMV's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Goodman New Zealand, Argan SA, Ashmore Group, Tri-Continental and more.

GIMV Overview

About GIMV

GIMV NV is a Belgium-based company active in investing in companies having growth potential, with the objective of supporting its growth into market leaders. The company invests with a focus on four platforms, which are also its segments: Consumer, Health and Care, Smart Industries, and Sustainable Cities. Its geographical segments include Belgium, Netherlands, Germany, France, and the Rest of Europe and Other countries.


Founded

1980

HQ

Belgium

Employees

94

Website

gimv.com

Financials (FY)

Revenue: $388M
Net Income: $251M

EV

$2.3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

GIMV Financials

GIMV reported last fiscal year revenue of $388M.

In the same fiscal year, GIMV generated $251M in net income.


GIMV P&L

In the most recent fiscal year, GIMV reported revenue of $388M and net income of $251M.

GIMV is profitable as of last fiscal year, with net margin of 65%.

See analyst estimates for GIMV
Last FY202320242025202620272028
Revenue$388M$243M$373M$388M
Net Profit$251M$170M$251M$251M
Net Margin65%70%67%65%

Financial data powered by Morningstar, Inc.

GIMV Stock Performance

GIMV has current market cap of $1.9B, and enterprise value of $2.3B.

Market Cap Evolution


GIMV's stock price is $50.87.

GIMV share price decreased by 3.8% in the last 30 days, and increased by 4.7% in the last year.

GIMV has an EPS (earnings per share) of $6.84.

See more trading valuation data for GIMV
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2.3B$1.9B-0.9%-3.8%-8.9%4.7%$6.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

GIMV Valuation Multiples

GIMV trades at 5.9x EV/Revenue multiple.

See NTM and 2027E valuation multiples for GIMV

GIMV Financial Valuation Multiples

As of July 18, 2026, GIMV has market cap of $1.9B and EV of $2.3B.

GIMV has a P/E ratio of 7.4x.

Last FY202320242025202620272028
EV/Revenue5.9x9.4x6.1x5.9x
P/E7.4x11.0x7.5x7.4x
EV/FCF(39.1x)(44.6x)(40.3x)(39.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified GIMV Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

GIMV Margins & Growth Rates

In the most recent fiscal year, GIMV reported net margin of 65%.

See estimated margins and future growth rates for GIMV

GIMV Margins

Last FY20242025202720282029
Net Margin65%67%65%
FCF Margin(15%)(15%)(15%)

GIMV Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth54%4%
Net Profit Growth48%0%
FCF Growth11%3%

Data powered by FactSet, Inc. and Morningstar, Inc.

GIMV Operational KPIs

GIMV's revenue per employee in the last FY averaged $4.1M, while opex per employee averaged $1.4M for the same period.

Access forward-looking KPIs for GIMV
Last FY202320242025202620272028
Revenue per Employee$4.1M---
Opex per Employee$1.4M---
S&M Expenses to Revenue-6%4%-
G&A Expenses to Revenue8%9%8%8%
Opex to Revenue35%29%33%35%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Goodman New Zealand14.4x17.7x(6.0x)19.4x
Argan SA13.5x15.5x11.8x16.4x
Ashmore Group4.8x5.0x6.2x15.7x
Tri-Continental7.5x---
Antin Infrastructure Partners4.4x4.4x7.7x8.2x
Montea16.4x18.1x13.6x18.8x
Tamburi Inv Partners163.3x719.1x27.6x(97.6x)
Israel Corp0.6x-3.3x-

This data is available for Pro users. Sign up to see all GIMV competitors and their valuation data.

Start Free Trial

Acquisitions by GIMV

GIMV has acquired 30 companies to date.

Last acquisition by GIMV was on June 24th 2026. GIMV acquired The Cap Vert Development Group for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by GIMV

The Cap Vert Development Group
Hemink Groep
Alpine
The Spice Factory
Description
The Cap Vert Development Group is a landscaping firm delivering comprehensive green space services across France, including landscape design, pruning, irrigation systems, fountain installation, and ongoing maintenance for public parks and private gardens. Paris-based with operations nationwide, the company manages over 5,000 sites for municipal governments and commercial clients like luxury hotels in Provence. Founded in 2005, it employs specialized teams for biodiversity enhancement projects using native plants in regions such as Normandy and the French Riviera. Recent contracts involve restoring historic gardens at Versailles and developing urban green roofs in Lyon.
Hemink Groep is a Dutch property service provider headquartered in Deventer delivering maintenance, renovation, and complete outfitting for residential and commercial buildings. The company handles electrical installations, HVAC systems, plumbing, and painting projects across the Netherlands. With a workforce specialized in multi-trade execution, Hemink Groep manages turnkey projects from initial assessment to final handover. Serving housing associations, property developers, and corporate clients, the firm emphasizes sustainable building practices and compliance with Dutch building codes.
Alpine Hearing Protection is a Netherlands-based manufacturer of custom-fit earplugs for musicians, motorsport enthusiasts, and industrial workers. Its product line includes models like MusicSafe, MotoSafe, and WorkSafe, sold through retailers in Europe and beyond.
The Spice Factory is a U.S.-based manufacturer and wholesaler of bulk herbs, spices, seasonings, and custom blends for foodservice, retail, and industrial clients. Operating from Ohio, it sources organic and conventional products including pepper, garlic, paprika, and spice mixes, offering private labeling, grinding, and packaging services compliant with FDA standards.
HQ CountryFranceNetherlandsNetherlandsBelgium
HQ City
Paris
Enschede
Utrecht
Braine-l'Alleud
Deal Date24 Jun 202622 Jul 202524 Jun 202520 Feb 2025
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all GIMV acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by GIMV

GIMV has invested in 39 companies to date.

Latest investment by GIMV was on January 20th 2026. GIMV invested in Exciva in their $60M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by GIMV

Exciva
Kinaset Therapeutics
spineart
Kivu Bioscience
Description
Exciva is a Heidelberg-based provider of targeted drug rescue programs for pharmaceutical research and development. The company develops symptomatic and disease-modifying treatments by repurposing approved drugs for new indications, including therapies, cures, prophylactics, supplements, and formulations. These efforts support healthcare organizations in rescuing and reusing existing drugs through specialized methods of production and application.
Kinaset Therapeutics is a Melbourne-headquartered clinical-stage company developing inhaled therapeutics for respiratory diseases. Its lead asset KIN-301 targets idiopathic pulmonary fibrosis with Phase 1 data showing safety in 50 patients. The pipeline includes candidates for COPD and asthma, licensed from Monash University research.
spineart designs and distributes sterile-packed implants with barcoded traceability and compact instrument sets from its Swiss operations. The portfolio covers minimally invasive surgery, motion preservation, fusion, biologics, and fracture treatments validated clinically for spine surgeons in Europe, Asia, and the Americas.
Kivu Bioscience is a biopharmaceutical company developing antibody-drug conjugates for oncology and immunology. Headquartered in Basel, Switzerland, it engineers site-specific ADCs with proprietary linkers and payloads for improved therapeutic indices. Kivu advances candidates like KV-001 targeting solid tumors through preclinical stages, leveraging platforms from former Roche scientists for scalable manufacturing.
HQ CountryGermanyUnited StatesSwitzerlandUnited States
HQ City
Heidelberg
Boston, MA
Geneva
San Francisco, CA
Deal Date20 Jan 202610 Jan 202626 Sep 202528 Oct 2024
RoundSeries BSeries BUndisclosed stageSeries A
Raised$60M$103M$31M$92M
InvestorsLBBW VC; EQT; GIMV; LifeArc Ventures; Andera Partners; Fountain Healthcare Partners; Carma Fund; Modi VenturesWillett Advisors LLC; 5AM Ventures; Sixty Degree Capital; EQT; Forge Life Science Partners; Atlas Venture; GIMV; Vivo Capital; RA Capital Management; Pictet Alternative Advisors; Schroders CapitalEGS Beteiligungen; GIMVM Ventures; HealthCap; Novo Holdings; Red Tree Venture Capital; GIMV; BOM; BioGeneration Ventures
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all GIMV investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About GIMV

When was GIMV founded?GIMV was founded in 1980.
Where is GIMV headquartered?GIMV is headquartered in Belgium.
How many employees does GIMV have?As of today, GIMV has over 94 employees.
Who is the CEO of GIMV?GIMV's CEO is Koen Dejonckheere.
Is GIMV publicly listed?Yes, GIMV is a public company listed on Euronext Brussels.
What is the stock symbol of GIMV?GIMV trades under GIMB ticker.
When did GIMV go public?GIMV went public in 1997.
Who are competitors of GIMV?GIMV main competitors include Goodman New Zealand, Argan SA, Ashmore Group, Tri-Continental, Antin Infrastructure Partners, Montea, Tamburi Inv Partners, Israel Corp, L1 Long Short Fund, Fortress Real Estate Investments.
What is the current market cap of GIMV?GIMV's current market cap is $1.9B.
What is the current revenue of GIMV?GIMV's last fiscal year revenue is $388M.
What is the current EV/Revenue multiple of GIMV?Current revenue multiple of GIMV is 5.9x.
Is GIMV profitable?No, GIMV is not profitable.
How many companies GIMV has acquired to date?As of July 2026, GIMV has acquired 30 companies.
What was the largest acquisition by GIMV?$259M acquisition of Smart Battery Solutions on 28th May 2019 was the largest M&A GIMV has done to date.
What companies GIMV acquired?GIMV acquired Smart Battery Solutions, Acceo, United Dutch Breweries, MVZ Holding, The Spice Factory, Variass, Verkley, Wemas Absperrtechnik, Wolf Lingerie, ALT Technologies, and 20 other companies.
In how many companies GIMV has invested to date?As of July 2026, GIMV has invested in 39 companies.
What was the last GIMV investment?On 20th January 2026 GIMV invested in Exciva, participating in a $60M Series B round, alongside LBBW VC, EQT, LifeArc Ventures, Andera Partners, Fountain Healthcare Partners, Carma Fund, and Modi Ventures.
In what companies GIMV invested in?GIMV invested in Kinaset Therapeutics, JenaValve Technology, Kivu Bioscience, Precirix, Mediar Therapeutics, Complement Therapeutics, ImmunOs Therapeutics, Covagen, Exciva, Anjarium Biosciences, Almaviva Santé, ImCheck Therapeutics, Lampiris, FIRE1, Breath Therapeutics, SynOx Therapeutics, iSTAR Medical, Endosense, Biotalys, Biom'Up, and 19 other companies.

See public comps similar to GIMV

Lists including GIMV

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial